https://aktiv8.io/news/nlq5slz/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with 2026-09-09 never 0.6 https://aktiv8.io/news/n1yzjdvx/revvity-to-acquire-human-cell-design-to-advance-human-relevant-cell-models-for-metabolic-d 2026-09-09 never 0.6 https://aktiv8.io/news/nzronca/harbour-biomed-partner-solstice-oncology-announces-225-million-series-a-financing-to-advan 2026-09-09 never 0.6 https://aktiv8.io/news/nrjngok/x4-pharmaceuticals-xfor-outlines-path-to-possible-2029-fda-approval-stock-titan 2026-09-09 never 0.6 https://aktiv8.io/news/n1hmufnv/partnership-for-quality-measurement-endorses-nkf-measure-to-advance-earlier-detection-of-c 2026-09-09 never 0.6 https://aktiv8.io/news/n1scx18w/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with 2026-09-09 never 0.6 https://aktiv8.io/news/nvendvr/beeline-flies-into-phase-3-as-oral-lupus-drug-soars-past-placebo 2026-09-09 never 0.6 https://aktiv8.io/news/nh5o51e/full-life-technologies-announces-u-s-fda-ind-clearance-and-australian-regulatory-clearance 2026-09-09 never 0.6 https://aktiv8.io/news/nnw4ddo/chilean-cobalt-corp-completes-phase-2-at-neore-rare-earth-project-advances-proposed-acquis 2026-09-09 never 0.6 https://aktiv8.io/news/n1s4a4ni/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-investing-com 2026-09-09 never 0.6 https://aktiv8.io/news/n1lgjimf/pyxis-oncology-announces-positive-updated-data-from-phase-1-monotherapy-study-of-micvotaba 2026-09-09 never 0.6 https://aktiv8.io/news/n188o6ra/just-evotec-biologics-advances-u-s-department-of-war-antibodies-against-orthopoxvirus-into 2026-09-09 never 0.6 https://aktiv8.io/news/n1l68mk8/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biotech-innova 2026-09-09 never 0.6 https://aktiv8.io/news/n1q35zic/solstice-rises-with-225m-series-a-to-advance-next-gen-ctla-4-immunotherapy-into-phase-2 2026-09-09 never 0.6 https://aktiv8.io/news/n6gdh8d/ideaya-biosciences-and-servier-announce-first-patient-dosed-in-optimum-11-global-phase-3-r 2026-09-09 never 0.6 https://aktiv8.io/news/ne0quln/ose-immunotherapeutics-welcomes-first-patient-dosed-by-veloxis-in-the-phase-2-rengevity-20 2026-09-09 never 0.6 https://aktiv8.io/news/n7i8m3q/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-o 2026-09-09 never 0.6 https://aktiv8.io/news/n3gsxis/hanchorbio-reaches-clinical-milestone-for-hcb101-as-us-fda-allows-continued-treatment-for- 2026-09-09 never 0.6 https://aktiv8.io/news/n18rva5a/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/nu3bkxq/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii- 2026-09-09 never 0.6 https://aktiv8.io/news/nzxpxn6/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/n1oht6rj/humacyte-announces-fda-authorization-extending-symvess-shelf-life-to-36-months 2026-09-09 never 0.6 https://aktiv8.io/news/njobtsx/taiwan-s-obigen-pharma-to-unblind-phase-3-botox-trial-early-in-november-year-end-cash-rais 2026-09-09 never 0.6 https://aktiv8.io/news/n1pistyo/emboline-receives-u-s-fda-510-k-clearance-for-emboliner-embolic-protection-system 2026-09-09 never 0.6 https://aktiv8.io/news/n8e5d6p/proqr-announces-first-participant-dosed-in-phase-1-study-of-ax-0811-and-virtual-investor-a 2026-09-09 never 0.6 https://aktiv8.io/news/n1q6gpre/radiopharm-theranostics-announces-positive-data-from-the-phase-1-imaging-trial-of-rad301-i 2026-09-09 never 0.6 https://aktiv8.io/news/n10gvh61/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital- 2026-09-09 never 0.6 https://aktiv8.io/news/n1ebo9tz/twostep-therapeutics-announces-oversubscribed-62-5-million-series-a-financing-and-fda-clea 2026-09-09 never 0.6 https://aktiv8.io/news/nfj3y6j/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplas 2026-09-09 never 0.6 https://aktiv8.io/news/n1rcm0fb/emulate-enters-final-stage-of-fda-istand-program-for-human-liver-chip-with-submission-of-q 2026-09-09 never 0.6 https://aktiv8.io/news/n1lzf369/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-develop-an-inh 2026-09-09 never 0.6 https://aktiv8.io/news/n1dynydg/sotio-doses-first-patient-in-phase-1-2-cadencia-01-clinical-trial-of-sot109-a-cdh17-target 2026-09-09 never 0.6 https://aktiv8.io/news/n1xuhxpv/ucb-receives-u-s-fda-breakthrough-therapy-designation-for-cimzia-certolizumab-pegol-in-pre 2026-09-09 never 0.6 https://aktiv8.io/news/n1r3jqx6/stat-pharmalittle-we-re-reading-about-an-astrazeneca-copd-win-the-fda-filling-key-jobs-and 2026-09-09 never 0.6 https://aktiv8.io/news/n30gby0/stat-arpa-h-to-invest-62-million-to-develop-fda-authorized-ai-to-help-treat-heart-failure 2026-09-09 never 0.6 https://aktiv8.io/news/n169vl91/seaport-therapeutics-reports-positive-topline-results-from-phase-1-driving-simulation-tria 2026-09-09 never 0.6 https://aktiv8.io/news/npkkipj/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-reduction- 2026-09-09 never 0.6 https://aktiv8.io/news/naj9ldm/massive-bio-and-precisca-announce-strategic-partnership-to-expand-cancer-patient-access-to 2026-09-09 never 0.6 https://aktiv8.io/news/n1jcfwwv/cranius-therapeutics-receives-fda-510-k-clearance-for-the-cranius-plate-a-patient-specific 2026-09-09 never 0.6 https://aktiv8.io/news/nps35kn/luma-vision-secures-fda-clearance-advancing-procedural-intelligence-as-the-foundation-of-t 2026-09-09 never 0.6 https://aktiv8.io/news/nb6wmor/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-padeliporfi 2026-09-09 never 0.6 https://aktiv8.io/news/n1lmdjfr/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/nidw29d/context-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ct-202-cntx-stock-n 2026-09-09 never 0.6 https://aktiv8.io/news/notvuuu/beeline-medicines-announces-positive-topline-results-from-global-phase-2-study-of-afimetor 2026-09-09 never 0.6 https://aktiv8.io/news/n1j7e6fw/evommune-gives-up-hope-for-mrgprx2-antagonist-to-treat-itch-after-latest-phase-2-fail 2026-09-09 never 0.6 https://aktiv8.io/news/nd3k7k5/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-develop-an-inh 2026-09-09 never 0.6 https://aktiv8.io/news/n1ylwmzt/adagene-achieves-milestone-in-collaboration-with-exelixis-for-advancement-of-safebody-anti 2026-09-09 never 0.6 https://aktiv8.io/news/nljsnqc/bms-reports-positive-data-from-phase-ii-quintessential-study-for-r-r-mm 2026-09-09 never 0.6 https://aktiv8.io/news/n16a17gx/pharvaris-charts-approval-course-for-swelling-disorder-drug-on-phase-iii-win 2026-09-09 never 0.6 https://aktiv8.io/news/n1m5axu9/tyra-biosciences-reports-initial-phase-2-surf302-results-supporting-the-first-potential-or 2026-09-09 never 0.6 https://aktiv8.io/news/n1iwjtww/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-o 2026-09-09 never 0.6 https://aktiv8.io/news/n1bbyct1/puretech-founded-entity-seaport-therapeutics-reports-positive-topline-results-from-phase-1 2026-09-09 never 0.6 https://aktiv8.io/news/ndb5w28/robinson-pharma-accelerates-southern-california-expansion-with-over-115-million-in-propert 2026-09-09 never 0.6 https://aktiv8.io/news/np61mdj/intelligent-bio-solutions-submits-fda-510-k-package-for-intelligent-fingerprinting-drug-sc 2026-09-09 never 0.6 https://aktiv8.io/news/n1h5eydf/amkor-technology-announces-phase-2-of-arizona-advanced-packaging-and-test-campus-expands-i 2026-09-08 never 0.6 https://aktiv8.io/news/n2mj08v/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally 2026-09-08 never 0.6 https://aktiv8.io/news/n1pkjp1f/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-prior 2026-09-08 never 0.6 https://aktiv8.io/news/ngg5sv8/can-fite-reports-q2-2026-financial-results-and-ongoing-clinical-progress-highlighting-long 2026-09-08 never 0.6 https://aktiv8.io/news/nswxwag/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-mo 2026-09-08 never 0.6 https://aktiv8.io/news/nwwfdx5/artiva-biotherapeutics-announces-planned-2026-data-readouts-and-phase-3-trial-initiation-f 2026-09-08 never 0.6 https://aktiv8.io/news/n1tcbxha/bioage-labs-announces-first-participant-dosed-in-quell-dme-a-phase-2-trial-of-bge-102-a-no 2026-09-08 never 0.6 https://aktiv8.io/news/nc0g2jx/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-test 2026-09-08 never 0.6 https://aktiv8.io/news/n7ksh51/fda-approves-astrazeneca-breast-cancer-drug 2026-09-08 never 0.6 https://aktiv8.io/news/nq9lpqm/can-fite-reports-q2-2026-financial-results-and-ongoing-clinical-progress-highlighting-long 2026-09-08 never 0.6 https://aktiv8.io/news/nobgslk/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-prior 2026-09-08 never 0.6 https://aktiv8.io/news/n1auw8iw/biovie-announces-update-to-parkinson-s-phase-3-development-program-stock-titan 2026-09-08 never 0.6 https://aktiv8.io/news/n1tmttly/intellia-announces-fda-acceptance-of-bla-for-lonvo-z-with-pdufa-date-march-10-2027-trading 2026-09-08 never 0.6 https://aktiv8.io/news/n9ahb41/biovie-announces-next-stage-of-fda-engagement-for-phase-3-parkinson-s-disease-program-eval 2026-09-08 never 0.6 https://aktiv8.io/news/n1an8pq4/moonwalk-to-use-70-million-to-develop-rnai-therapies-for-obesity-cardiometabolic-disease 2026-09-08 never 0.6 https://aktiv8.io/news/nv8f2yk/biotech-filed-for-bankruptcy-11-weeks-before-its-big-fda-decision-thestreet-com 2026-09-08 never 0.6 https://aktiv8.io/news/nk1yv4p/taiwan-s-horien-accelerates-global-footprint-achieves-three-thai-fda-class-4-approvals-and 2026-09-08 never 0.6 https://aktiv8.io/news/nktdmuu/alebund-pharmaceuticals-announces-fda-clearance-of-ind-application-for-ap308-for-the-treat 2026-09-08 never 0.6 https://aktiv8.io/news/n1p7da0l/kelun-biotech-s-partner-windward-bio-announces-positive-phase-2-results-of-skb378-win378-i 2026-09-08 never 0.6 https://aktiv8.io/news/n1cj0tlw/genflow-biosciences-plc-announces-primary-endpoint-in-slab-clinical-trial-met-genff-stock- 2026-09-08 never 0.6 https://aktiv8.io/news/nuvebtx/alebund-pharmaceuticals-announces-fda-clearance-of-ind-application-for-ap308-for-the-treat 2026-09-08 never 0.6 https://aktiv8.io/news/nmyid4t/ribox-therapeutics-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designatio 2026-09-08 never 0.6 https://aktiv8.io/news/n1nurpbf/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-test 2026-09-08 never 0.6 https://aktiv8.io/news/n121c4v5/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally 2026-09-08 never 0.6 https://aktiv8.io/news/n14ogl5v/roivant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pulmo 2026-09-08 never 0.6 https://aktiv8.io/news/n1n6fqb0/structure-therapeutics-reports-positive-clinical-data-across-oral-small-molecule-amylin-an 2026-09-08 never 0.6 https://aktiv8.io/news/n1nq6dq/semaglutide-improves-bmi-category-in-phase-3-pediatric-obesity-trial-patient-care-online 2026-09-08 never 0.6 https://aktiv8.io/news/n10h79vq/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-ra 2026-09-08 never 0.6 https://aktiv8.io/news/n1eayudz/belite-bio-announces-submission-of-new-drug-application-to-the-ministry-of-health-labour-a 2026-09-08 never 0.6 https://aktiv8.io/news/n1uiaove/sernova-and-seraxis-enter-definitive-merger-agreement-to-create-a-differentiated-type-1-di 2026-09-08 never 0.6 https://aktiv8.io/news/n5rua8t/novo-nordisk-s-wegovy-helps-free-40-of-kids-from-obesity-in-phase-3-trial-fierce-pharma 2026-09-08 never 0.6 https://aktiv8.io/news/n1lrx88z/dyne-therapeutics-to-present-additional-one-year-clinical-data-from-phase-1-2-achieve-tria 2026-09-08 never 0.6 https://aktiv8.io/news/nqpfkzq/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-mo 2026-09-08 never 0.6 https://aktiv8.io/news/nta9nwz/newron-secures-eur-5-5m-financing-for-evenamide-phase-3-program-wboc-tv 2026-09-08 never 0.6 https://aktiv8.io/news/nzutuem/a-breakthrough-blood-test-for-prostate-cancer-to-be-premiered-by-5q-spectra-at-davos-of-he 2026-09-08 never 0.6 https://aktiv8.io/news/n6d3wn/metashape-pharma-to-showcase-new-data-and-strategic-updates-at-medinvest-and-resi-life-sci 2026-09-08 never 0.6 https://aktiv8.io/news/n1xoej9g/kiora-pharmaceuticals-appoints-keith-j-lane-as-executive-vice-president-of-global-clinical 2026-09-08 never 0.6 https://aktiv8.io/news/n1cyotmu/pepromene-bio-annonce-la-publication-dans-the-lancet-des-resultats-d-un-essai-clinique-de- 2026-09-08 never 0.6 https://aktiv8.io/news/n1de1d1s/accro-bioscience-announces-ind-clearance-from-nmpa-for-phase-ii-iii-clinical-trial-of-ac-2 2026-09-08 never 0.6 https://aktiv8.io/news/n8i7qs8/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-part-of-up- 2026-09-08 never 0.6 https://aktiv8.io/news/n1n2re41/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phase-2-quinte 2026-09-08 never 0.6 https://aktiv8.io/news/n1xc33o3/orphalan-initiates-global-phase-3-traditional-study-of-investigational-once-daily-trientin 2026-09-08 never 0.6 https://aktiv8.io/news/n27c22x/applied-biologics-welcomes-new-cms-rapid-pathway-and-expanded-cms-fda-coordination-for-inn 2026-09-08 never 0.6 https://aktiv8.io/news/n141pond/kelun-biotech-s-partner-windward-bio-announces-positive-phase-2-results-of-skb378-win378-i 2026-09-08 never 0.6 https://aktiv8.io/news/n3i4j27/a-quarterly-dose-cut-asthma-flare-ups-56-versus-a-dummy-treatment-upstream-bio-plans-phase 2026-09-08 never 0.6 https://aktiv8.io/news/n7ca5r3/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-ra 2026-09-08 never 0.6 https://aktiv8.io/news/nldtyfd/pharvaris-latest-phase-3-win-builds-case-for-hae-drug-with-fda-verdict-pending 2026-09-08 never 0.6 https://aktiv8.io/news/n144qozp/adlai-nortye-announces-first-patient-dosed-in-australia-and-u-s-fda-ind-clearance-for-an40 2026-09-08 never 0.6 https://aktiv8.io/news/n1wwjnnk/pharvaris-announces-positive-topline-data-from-chapter-3-pivotal-study-of-deucrictibant-xr 2026-09-08 never 0.6 https://aktiv8.io/news/n52l9n6/probiogen-grants-transgene-additional-license-for-age1-cr-pix-cell-line 2026-09-08 never 0.6 https://aktiv8.io/news/nenrl9s/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-part-of-up- 2026-09-08 never 0.6 https://aktiv8.io/news/nim6a1a/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phase-2-quinte 2026-09-08 never 0.6 https://aktiv8.io/news/n1bzpxru/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally 2026-09-08 never 0.6 https://aktiv8.io/news/nirkqgu/altesa-biosciences-presents-novel-clinical-data-demonstrating-vapendavir-significantly-red 2026-09-08 never 0.6 https://aktiv8.io/news/n1y89bkx/pharvaris-latest-phase-3-win-builds-case-for-hae-drug-with-fda-verdict-pending 2026-09-08 never 0.6 https://aktiv8.io/news/nrbul0r/pharvaris-announces-positive-phase-3-results-for-deucrictibant-xr-in-hereditary-angioedema 2026-09-08 never 0.6 https://aktiv8.io/news/n19zuyw6/helixgate-biotech-review-brings-helixgate-ai-biotech-collaboration-series-and-helixgate-in 2026-09-08 never 0.6 https://aktiv8.io/news/n1hhdh13/oral-obesity-drug-shows-double-digit-weight-loss-as-structure-therapeutics-nasdaq-gpcr-adv 2026-09-08 never 0.6 https://aktiv8.io/news/n1ap1dy6/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/n1d0zml2/stat-fda-names-acting-heads-of-drug-and-vaccine-centers-to-permanent-roles 2026-09-08 never 0.6 https://aktiv8.io/news/nby33xd/clearmind-medicine-receives-yale-irb-approval-enabling-patient-recruitment-for-parts-b-and 2026-09-08 never 0.6 https://aktiv8.io/news/ndln6qz/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lp-a-horizons-biospace 2026-09-08 never 0.6 https://aktiv8.io/news/n1nhqbqr/can-fite-reports-q2-2026-financial-results-and-ongoing-clinical-progress-highlighting-long 2026-09-08 never 0.6 https://aktiv8.io/news/n2su6ow/adlai-nortye-announces-first-patient-dosed-in-australia-and-u-s-fda-ind-clearance-for-an40 2026-09-08 never 0.6 https://aktiv8.io/news/n3ea0rp/accro-bioscience-announces-ind-clearance-from-nmpa-for-phase-ii-iii-clinical-trial-of-ac-2 2026-09-08 never 0.6 https://aktiv8.io/news/n1ndt7vo/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/n16lm05i/medicure-presents-mend-pnpo-phase-3-study-design-and-baseline-data-at-the-16th-european-ep 2026-09-08 never 0.6 https://aktiv8.io/news/n6elm7/vor-biopharma-vor-completes-enrollment-in-phase-3-trial-as-market-eyes-growth-potential-gu 2026-09-08 never 0.6 https://aktiv8.io/news/n16fzq17/bristol-myers-pivotal-car-t-multiple-myeloma-trial-hits-primary-endpoint 2026-09-08 never 0.6 https://aktiv8.io/news/nfwowc3/stat-fda-warns-an-api-supplier-about-residue-on-walls-a-corroded-product-line-and-open-toe 2026-09-08 never 0.6 https://aktiv8.io/news/nf1l5a7/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-a 2026-09-08 never 0.6 https://aktiv8.io/news/njkohfn/biovie-advances-parkinson-s-phase-3-trial-plans-after-positive-phase-2-results-and-fda-eng 2026-09-08 never 0.6 https://aktiv8.io/news/n1xfdso2/sernova-and-seraxis-enter-definitive-merger-agreement-to-create-a-differentiated-type-1-di 2026-09-08 never 0.6 https://aktiv8.io/news/n1fb7321/stat-fda-approves-astrazeneca-breast-cancer-drug 2026-09-08 never 0.6 https://aktiv8.io/news/n6kyuo9/pulmovant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pul 2026-09-08 never 0.6 https://aktiv8.io/news/n8hs1p3/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/n163nldv/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabeti 2026-09-08 never 0.6 https://aktiv8.io/news/nj14uvh/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitacicept-glob 2026-09-08 never 0.6 https://aktiv8.io/news/nf80f6e/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-prior 2026-09-08 never 0.6 https://aktiv8.io/news/n17yict6/abbott-receives-fda-approval-for-its-tactiflex-duo-ablation-catheter-to-treat-people-with- 2026-09-08 never 0.6 https://aktiv8.io/news/n34j9g5/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-initiation-of-phas 2026-09-08 never 0.6 https://aktiv8.io/news/n2mpm38/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatmen 2026-09-08 never 0.6 https://aktiv8.io/news/n1xhmdfz/ge-healthcare-aims-to-advance-a-new-era-in-theranostics-with-starguide-gx-4d-spect-ct-now- 2026-09-08 never 0.6 https://aktiv8.io/news/nem0b2c/dyne-therapeutics-to-present-additional-one-year-clinical-data-from-phase-1-2-achieve-tria 2026-09-08 never 0.6 https://aktiv8.io/news/n1quas3p/labcorp-acquires-mlm-medical-labs-expanding-global-central-laboratory-and-biomarker-capabi 2026-09-08 never 0.6 https://aktiv8.io/news/n14m2kw5/upstream-bio-reports-phase-2-valiant-trial-results-showing-verekitug-reduced-severe-asthma 2026-09-08 never 0.6 https://aktiv8.io/news/n1quv7ft/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/ntpnbwz/protocol-behavioral-health-partners-with-new-york-cancer-blood-specialists-to-bring-integr 2026-09-08 never 0.6 https://aktiv8.io/news/nkzwexx/veru-advances-oral-sabizabulin-following-positive-preclinical-data-showing-potent-anticanc 2026-09-08 never 0.6 https://aktiv8.io/news/n1q1qigp/biovie-announces-update-to-parkinson-s-phase-3-development-program-bivi-stock-news 2026-09-08 never 0.6 https://aktiv8.io/news/n1vb27pm/new-labcentral-program-the-loop-offers-international-biotech-start-ups-and-partner-organiz 2026-09-08 never 0.6 https://aktiv8.io/news/n1cty5y2/palantir-and-nebius-partner-to-deliver-a-complete-sovereign-ai-stack-to-palantir-customers 2026-09-08 never 0.6 https://aktiv8.io/news/nkbkf60/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-mo 2026-09-08 never 0.6 https://aktiv8.io/news/nzps7jf/amgen-announces-landmark-results-from-the-phase-3-dellphi-305-study-demonstrating-statisti 2026-09-08 never 0.6 https://aktiv8.io/news/n3arwsw/labcorp-acquires-mlm-medical-labs-expanding-global-central-laboratory-and-biomarker-capabi 2026-09-08 never 0.6 https://aktiv8.io/news/nwig44r/sudarshan-pharma-industries-to-acquire-9-5-stake-in-us-based-medtherapy-biotech-outlookbus 2026-09-08 never 0.6 https://aktiv8.io/news/nuwnmh1/new-labcentral-program-the-loop-offers-international-biotech-start-ups-and-partner-organiz 2026-09-08 never 0.6 https://aktiv8.io/news/nwlsung/biovie-announces-update-to-parkinson-s-phase-3-development-program 2026-09-08 never 0.6 https://aktiv8.io/news/n1etao4n/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-initiation-of-phas 2026-09-08 never 0.6 https://aktiv8.io/news/nf5a2s7/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-win 2026-09-08 never 0.6 https://aktiv8.io/news/nacuq0t/novo-nordisk-step-young-phase-3-data-40-4-of-children-living-with-obesity-achieved-a-bmi-b 2026-09-07 never 0.6 https://aktiv8.io/news/nxcb5kz/acepodia-secures-fda-clearance-to-begin-phase-i-ace723-trial 2026-09-07 never 0.6 https://aktiv8.io/news/n36e79w/novartis-pelacarsen-fails-to-meet-primary-endpoint-in-lp-a-horizon-trial 2026-09-07 never 0.6 https://aktiv8.io/news/n8m1zl3/hagens-berman-alerts-capricor-therapeutics-inc-nasdaq-capr-investors-to-fda-review-extensi 2026-09-07 never 0.6 https://aktiv8.io/news/niciw0n/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-07 never 0.6 https://aktiv8.io/news/n2ltgdj/sudarshan-pharma-industries-to-acquire-9-5-stake-in-us-based-medtherapy-biotech-thebluntti 2026-09-07 never 0.6 https://aktiv8.io/news/nfkqram/novo-nordisk-step-young-phase-3-data-40-4-of-children 2026-09-07 never 0.6 https://aktiv8.io/news/n1u8h28c/sudarshan-pharma-acquires-9-5-in-medtherapy-vohnetwork-com 2026-09-07 never 0.6 https://aktiv8.io/news/nppcw2i/brainchild-bio-masterminds-116m-series-a-for-car-t-s-pivotal-push-in-pediatric-brain-cance 2026-09-07 never 0.6 https://aktiv8.io/news/n1qpshjw/novartis-lp-a-drug-misses-phase-3-endpoint-european-biotechnology-magazine 2026-09-07 never 0.6 https://aktiv8.io/news/nay31s0/clover-announces-positive-phase-2-clinical-data-for-rsv-hmpv-piv3-respiratory-combination- 2026-09-06 never 0.6 https://aktiv8.io/news/n1tzwfic/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-win 2026-09-06 never 0.6 https://aktiv8.io/news/n1jtkpe4/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat-in-patient 2026-09-06 never 0.6 https://aktiv8.io/news/n7fjjw6/will-positive-phase-3-deucrictibant-data-in-hae-redefine-pharvaris-phvs-orphan-drug-narrat 2026-09-05 never 0.6 https://aktiv8.io/news/n1m19x88/crispr-therapeutics-gains-fda-approval-for-casg-pluang 2026-09-05 never 0.6 https://aktiv8.io/news/n1kf1r4a/sudarshan-pharma-acquires-9-50-stake-in-us-firm-medtherapy-biotech-scanx-trade 2026-09-05 never 0.6 https://aktiv8.io/news/niyrq7a/inhibrx-to-present-inbrx-106-phase-2-data-in-head-and-neck-cancer-study-the-clinical-trial 2026-09-05 never 0.6 https://aktiv8.io/news/nhtw683/pelacarsen-fails-to-meet-primary-endpoint-in-phase-3-lp-a-trial-the-clinical-trial-vanguar 2026-09-05 never 0.6 https://aktiv8.io/news/n1dqvmjn/acepodia-announces-fda-clearance-of-ind-application-for-ace723-a-novel-dual-payload-antibo 2026-09-04 never 0.6 https://aktiv8.io/news/nwanstx/this-biotech-wins-a-big-fda-approval-why-wall-street-is-shrugging-barron-s 2026-09-04 never 0.6 https://aktiv8.io/news/njejh9g/guardant-health-announces-landmark-fda-approval-of-guardant360 2026-09-04 never 0.6 https://aktiv8.io/news/nxmq2r5/acepodia-announces-fda-clearance-of-ind-application-for-ace723-a-novel-dual-payload-antibo 2026-09-04 never 0.6 https://aktiv8.io/news/n7ipwe5/medicus-pharma-licenses-pfizer-s-discontinued-cd228-targeted-adc-in-deal-worth-over-1-bill 2026-09-04 never 0.6 https://aktiv8.io/news/n106hagj/ionis-rare-neurology-drug-approved-pfizer-inks-an-adc-deal 2026-09-04 never 0.6 https://aktiv8.io/news/n1744viz/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inbrx-106-pha 2026-09-04 never 0.6 https://aktiv8.io/news/nw5jszf/sensorion-secures-approval-for-hearconnex-phase-i-ii-study-in-france 2026-09-04 never 0.6 https://aktiv8.io/news/n1mckfa9/lupin-receives-u-s-fda-approval-for-modafinil-tablets-usp 2026-09-04 never 0.6 https://aktiv8.io/news/n1fohdns/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the- 2026-09-04 never 0.6 https://aktiv8.io/news/n1nj8132/medicus-pharma-licenses-shelved-pfizer-melanoma-adc-in-deal-worth-up-to-1b-dealroom 2026-09-04 never 0.6 https://aktiv8.io/news/nq383lw/this-week-in-charts-china-deals-stock-flatlines-and-lilly-s-m-a-spree 2026-09-04 never 0.6 https://aktiv8.io/news/nvy6idv/constar-factory-announces-fda-510-k-cleared-contact-lens-oem-solutions-for-us-importers-an 2026-09-04 never 0.6 https://aktiv8.io/news/n3iut9d/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-04 never 0.6 https://aktiv8.io/news/n6ee32f/c4x-discovery-to-receive-milestone-payment-for-nrf2-exclusive-worldwide-license-agreement 2026-09-04 never 0.6 https://aktiv8.io/news/nz6qdtq/lupin-receives-u-s-fda-approval-for-modafinil-tablets-usp 2026-09-04 never 0.6 https://aktiv8.io/news/nyc8rok/stat-novartis-experimental-cardiovascular-drug-fails-a-pivotal-study 2026-09-04 never 0.6 https://aktiv8.io/news/nuxqkpf/abbvie-abbv-reports-positive-phase-3-results-for-etentamig-in-multiple-myeloma 2026-09-04 never 0.6 https://aktiv8.io/news/n1isywyo/cluepoints-launches-ai-tools-for-clinical-data-review-with-top-10-pharma-partner-the-clini 2026-09-04 never 0.6 https://aktiv8.io/news/ncg8v3l/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacarsen-the-man 2026-09-04 never 0.6 https://aktiv8.io/news/nf645da/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the- 2026-09-04 never 0.6 https://aktiv8.io/news/nf0eq0x/the-friday-brief-for-september-4-2026-licensing-deals-dominate-the-week-contract-pharma 2026-09-04 never 0.6 https://aktiv8.io/news/nhqck8c/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pelacarsen-in-patients-with- 2026-09-04 never 0.6 https://aktiv8.io/news/n18q8ftn/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacarsen-rprx-st 2026-09-04 never 0.6 https://aktiv8.io/news/n19yrqmf/stat-fda-takes-another-look-at-botanical-drugs 2026-09-04 never 0.6 https://aktiv8.io/news/nmp8c7w/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-04 never 0.6 https://aktiv8.io/news/n1fp0jay/sino-biopharmaceutical-s-gpc3-adc-drug-wins-fda-clinical-trial-approval-shares-surge-nearl 2026-09-04 never 0.6 https://aktiv8.io/news/n10fvjuz/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-04 never 0.6 https://aktiv8.io/news/n1akans4/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inbrx-106-pha 2026-09-04 never 0.6 https://aktiv8.io/news/n1yjktp/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-04 never 0.6 https://aktiv8.io/news/ny811x3/ivonescimab-beats-pembrolizumab-on-overall-survival-in-phase-3-nsclc-trial-clinicaltrialva 2026-09-04 never 0.6 https://aktiv8.io/news/n1br3s9t/kali-therapeutics-receives-u-s-fda-clearance-for-kt501-investigational-new-drug-applicatio 2026-09-03 never 0.6 https://aktiv8.io/news/n1nluiuf/leqembi-lecanemab-subcutaneous-formulation-as-an-initiation-treatment-for-early-alzheimer- 2026-09-03 never 0.6 https://aktiv8.io/news/nnbxdwz/eledon-pharmaceuticals-announces-islet-cell-transplantation-ind-submission-first-patients- 2026-09-03 never 0.6 https://aktiv8.io/news/ng1aexd/stat-fda-pilot-offers-generative-ai-medical-devices-a-path-to-patients-before-they-are-aut 2026-09-03 never 0.6 https://aktiv8.io/news/nxgiy8h/tangram-therapeutics-announces-progression-to-patient-cohorts-in-phase-1-2-restore-mash-tr 2026-09-03 never 0.6 https://aktiv8.io/news/n18xa2et/eledon-pharmaceuticals-announces-islet-cell-transplantation-ind-submission-first-patients- 2026-09-03 never 0.6 https://aktiv8.io/news/n1ho9c2g/north-shore-intersects-significant-uranium-mineralization-in-all-phase-1-drill-holes-at-ri 2026-09-03 never 0.6 https://aktiv8.io/news/nak8h72/stat-abivax-has-still-not-been-acquired-what-s-going-on 2026-09-03 never 0.6 https://aktiv8.io/news/n2etaay/c4-therapeutics-to-present-new-biomarker-data-on-the-immunomodulatory-effects-of-cemsidomi 2026-09-03 never 0.6 https://aktiv8.io/news/n1ivfsm8/climb-bio-announces-clym116-phase-1-data-demonstrating-globenewswire-com 2026-09-03 never 0.6 https://aktiv8.io/news/nyn20tj/legacy-healthcare-welcomes-u-s-congressional-legislation-proposing-12-year-market-exclusiv 2026-09-03 never 0.6 https://aktiv8.io/news/n57pvek/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/n128hk3m/cipla-qilu-enter-licensing-and-supply-deal-for-keytruda-biosimilar-in-us-contract-pharma 2026-09-03 never 0.6 https://aktiv8.io/news/n1j0jy2u/ionis-wins-fda-approval-for-first-drug-for-alexander-disease-a-rare-and-deadly-neurologica 2026-09-03 never 0.6 https://aktiv8.io/news/n1qc50iu/norroy-receives-china-s-clearance-for-phase-iii-study-of-177lu-nym032 2026-09-03 never 0.6 https://aktiv8.io/news/nj38hnr/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-03 never 0.6 https://aktiv8.io/news/n1kbz2w3/vaxcyte-appoints-chief-medical-officer-and-chief-legal-officer-narrows-guidance-for-expect 2026-09-03 never 0.6 https://aktiv8.io/news/n1rzkq61/thryv-therapeutics-licenses-a-new-class-of-sgk1-inhibitors-from-spain-s-csic-and-universid 2026-09-03 never 0.6 https://aktiv8.io/news/n1jxw09e/matricelf-receives-fda-feedback-supporting-key-elements-of-proposed-first-in-human-clinica 2026-09-03 never 0.6 https://aktiv8.io/news/nkeydhr/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductions 2026-09-03 never 0.6 https://aktiv8.io/news/nmtijid/legacy-healthcare-welcomes-u-s-congressional-legislation-proposing-12-year-market-exclusiv 2026-09-03 never 0.6 https://aktiv8.io/news/nqx472o/climb-bio-announces-clym116-phase-1-data-demonstrating-prolonged-half-life-and-best-in-cla 2026-09-03 never 0.6 https://aktiv8.io/news/n19dkz7c/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductions 2026-09-03 never 0.6 https://aktiv8.io/news/naaiym1/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-03 never 0.6 https://aktiv8.io/news/ngx7c5q/opinion-stat-a-surprising-bright-spot-at-the-fda-on-regulating-unproven-stem-cells 2026-09-03 never 0.6 https://aktiv8.io/news/nufbyu0/gsk-inks-another-asia-alliance-betting-up-to-1-3b-for-hutchmed-s-cancer-therapy 2026-09-03 never 0.6 https://aktiv8.io/news/n2w3v9f/fda-approves-ionis-antisense-drug-as-first-targeted-therapy-for-alexander-disease-biospace 2026-09-03 never 0.6 https://aktiv8.io/news/n19vdibk/vaxcyte-inc-pcvx-updates-phase-3-trial-timeline-market-pricing-reflects-growth-expectation 2026-09-03 never 0.6 https://aktiv8.io/news/n9nr2s4/perfect-game-launches-new-global-country-partner-program-to-expand-international-baseball- 2026-09-03 never 0.6 https://aktiv8.io/news/n1yz7zls/stat-ionis-wins-fda-approval-for-first-drug-for-alexander-disease-a-rare-and-deadly-neurol 2026-09-03 never 0.6 https://aktiv8.io/news/n1fsahsx/capricor-replimune-illustrate-why-fda-must-listen-to-rare-disease-specialists 2026-09-03 never 0.6 https://aktiv8.io/news/n1ot5961/gan-lee-and-menarini-group-partner-to-advance-bofanglutide-in-europe 2026-09-03 never 0.6 https://aktiv8.io/news/n1hkziau/hutchmed-strikes-licensing-agreement-with-gsk-the-pharma-letter 2026-09-03 never 0.6 https://aktiv8.io/news/n1w73rz9/matricelf-receives-fda-feedback-supporting-key-elements-of-proposed-first-in-human-clinica 2026-09-03 never 0.6 https://aktiv8.io/news/n1wq7lsy/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/n1o1sta8/c4-therapeutics-to-present-new-biomarker-data-on-the-immunomodulatory-effects-of-cemsidomi 2026-09-03 never 0.6 https://aktiv8.io/news/n18ry65m/kali-therapeutics-receives-u-s-fda-clearance-for-kt501-investigational-new-drug-applicatio 2026-09-03 never 0.6 https://aktiv8.io/news/n1074j1d/ultragenyx-drops-on-phase-3-trial-failure-for-angelman-syndrome-drug-rare-nasdaq 2026-09-03 never 0.6 https://aktiv8.io/news/n18p6z55/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-th 2026-09-03 never 0.6 https://aktiv8.io/news/nyv37qg/revmed-s-newly-approved-rasonque-could-hold-up-in-non-small-cell-lung-cancer-biospace 2026-09-03 never 0.6 https://aktiv8.io/news/n1hcv4q0/climb-bio-announces-clym116-phase-1-data-demonstrating-prolonged-half-life-and-best-in-cla 2026-09-03 never 0.6 https://aktiv8.io/news/nq98zbh/cellipont-bioservices-texas-facility-has-supported-six-client-projects-expected-to-reach-i 2026-09-03 never 0.6 https://aktiv8.io/news/nbqe4dj/treeline-and-roche-collaborate-on-tln-121-combo-trial-for-bcl 2026-09-03 never 0.6 https://aktiv8.io/news/nla8fiz/ultragenyx-s-apazunersen-fails-phase-3-angelman-syndrome-trial-biopharm-international 2026-09-03 never 0.6 https://aktiv8.io/news/nrypbee/pfizer-licenses-discontinued-cancer-drug-to-medicus-pharma-in-deal-valued-over-1-billion-f 2026-09-03 never 0.6 https://aktiv8.io/news/n17irvq3/medicus-pharma-inks-global-licensing-deal-with-pfizer-worth-over-1-billion-benzinga 2026-09-03 never 0.6 https://aktiv8.io/news/n1txr4lr/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/n1o40tni/ivonescimab-meets-overall-survival-endpoint-against-pembrolizumab-in-phase-iii-trial-the-c 2026-09-03 never 0.6 https://aktiv8.io/news/n1vzbmd3/boehringer-ingelheim-lifebit-extend-clinical-data-partnership-contract-pharma 2026-09-03 never 0.6 https://aktiv8.io/news/ni5n6d3/ultragenyx-s-apazunersen-fails-phase-3-primary-endpoint-in-angelman-syndrome-the-clinical- 2026-09-03 never 0.6 https://aktiv8.io/news/n1vm2qim/energy-vault-accelerates-125-mw-1-gwh-stoney-creek-bess-toward-construction-with-full-proj 2026-09-03 never 0.6 https://aktiv8.io/news/no54h7g/south-korean-biotech-licensing-deals-top-21-trillion-but-stock-prices-lag-recovery-hinges- 2026-09-03 never 0.6 https://aktiv8.io/news/ng398if/hutchmed-partners-with-gsk-to-develop-first-in-class-cancer-drug-in-licensing-deal-worth-u 2026-09-03 never 0.6 https://aktiv8.io/news/n1j3qnvr/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/n1mq5qnw/fda-files-reveal-lingering-concerns-contrasting-views-behind-replimune-melanoma-nod-fierce 2026-09-03 never 0.6 https://aktiv8.io/news/n1m4mq49/sensorion-announces-approval-of-clinical-trial-application-in-france-for-sens-601-its-inve 2026-09-03 never 0.6 https://aktiv8.io/news/njtvffk/matricelf-receives-fda-feedback-supporting-key-elements-of-proposed-first-in-human-clinica 2026-09-03 never 0.6 https://aktiv8.io/news/n9ycsuv/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-03 never 0.6 https://aktiv8.io/news/nal4xs5/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-b 2026-09-02 never 0.6 https://aktiv8.io/news/nhm052z/ono-pharma-enters-into-a-drug-discovery-partnership-with-aitia-in-neurological-diseases 2026-09-02 never 0.6 https://aktiv8.io/news/nol9sr0/abbvie-s-rinvoq-restores-80-hair-growth-in-severe-alopecia-areata-phase-3-trial-south-kore 2026-09-02 never 0.6 https://aktiv8.io/news/n1of4sjw/uniqure-announces-submission-of-biologics-license-application-for-ifezuntirgene-inilparvov 2026-09-02 never 0.6 https://aktiv8.io/news/n1jvdwfz/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines- 2026-09-02 never 0.6 https://aktiv8.io/news/nwt5z7p/revamped-plan-aims-to-hasten-us-approval-of-treatment-for-als-als-news-today 2026-09-02 never 0.6 https://aktiv8.io/news/nmkomn2/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liv 2026-09-02 never 0.6 https://aktiv8.io/news/n16lmlzj/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-unce 2026-09-02 never 0.6 https://aktiv8.io/news/njpucvh/uniqure-files-for-fda-uk-approval-of-first-gene-therapy-for-huntington-s-disease-biospace 2026-09-02 never 0.6 https://aktiv8.io/news/nj33oyx/heartvue-ai-and-innolitics-achieve-fda-510-k-clearance-for-heartvue-proton-an-ai-powered-c 2026-09-02 never 0.6 https://aktiv8.io/news/n3m14v1/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutical-for-a-fu 2026-09-02 never 0.6 https://aktiv8.io/news/n1g0ig89/united-therapeutics-corporation-announces-fda-acceptance-of-supplemental-new-drug-applicat 2026-09-02 never 0.6 https://aktiv8.io/news/n1du3x7g/united-therapeutics-corporation-announces-fda-acceptance-of-supplemental-new-drug-applicat 2026-09-02 never 0.6 https://aktiv8.io/news/ndxav0c/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-unce 2026-09-02 never 0.6 https://aktiv8.io/news/n17fk5kj/owkin-signs-ai-drug-discovery-deal-with-boehringer-for-cancer-immunology 2026-09-02 never 0.6 https://aktiv8.io/news/n1of6bzp/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines- 2026-09-02 never 0.6 https://aktiv8.io/news/n97o0r/visionary-receives-phase-2-drill-approval-for-its-pt-leamington-gold-copper-zinc-silver-vm 2026-09-02 never 0.6 https://aktiv8.io/news/nxutj3v/ono-pharma-and-aitia-announce-collaboration-to-identify-novel-drug-targets-in-neurological 2026-09-02 never 0.6 https://aktiv8.io/news/nsnay2c/teva-announces-positive-topline-results-from-phase-2a-study-in-celiac-disease-for-its-anti 2026-09-02 never 0.6 https://aktiv8.io/news/n1djsz7v/bayesian-health-s-fda-cleared-continuous-ai-sepsis-monitor-approved-for-medicare-new-techn 2026-09-02 never 0.6 https://aktiv8.io/news/n1c0mqq2/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway 2026-09-02 never 0.6 https://aktiv8.io/news/n1dguc4y/raziel-therapeutics-and-fosun-pharma-announce-positive-phase-3-results-for-rzl-012-in-subm 2026-09-02 never 0.6 https://aktiv8.io/news/n5471tu/newbiologix-and-synastra-biotechnology-partner-to-advance-stable-raav-manufacturing-for-du 2026-09-02 never 0.6 https://aktiv8.io/news/n1i326qi/cipla-signs-exclusive-licensing-deal-with-sbp-group-for-her2-targeted-adc-express-pharma 2026-09-02 never 0.6 https://aktiv8.io/news/ntp0x4c/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liv 2026-09-02 never 0.6 https://aktiv8.io/news/n1g9wqmh/fda-raises-bar-for-foreign-site-inspections-as-china-trials-surge 2026-09-02 never 0.6 https://aktiv8.io/news/n1ac13lr/simcere-inks-license-agreement-with-roche-for-sim0660-the-pharma-letter 2026-09-02 never 0.6 https://aktiv8.io/news/nwt5tns/alteogen-signs-3-2b-alt-b4-licensing-deal-with-novartis-contract-pharma 2026-09-02 never 0.6 https://aktiv8.io/news/n15uy8tr/acto-achieves-veeva-gold-product-partner-status-following-a-nearly-decade-long-collaborati 2026-09-02 never 0.6 https://aktiv8.io/news/n1lcze5n/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liv 2026-09-02 never 0.6 https://aktiv8.io/news/n146ejvc/ultragenyx-announces-phase-3-aspire-results-in-angelman-syndrome-rare-stock-news 2026-09-02 never 0.6 https://aktiv8.io/news/nyg6wb9/global-pharma-m-a-why-drugmakers-are-turning-to-biotech-for-growth-expert-view-by-spherica 2026-09-02 never 0.6 https://aktiv8.io/news/n3wtbql/sec-fda-sign-info-sharing-agreement-as-a-signal-to-the-market-on-insider-trading 2026-09-02 never 0.6 https://aktiv8.io/news/nieueek/novartis-and-bms-paused-car-t-trials-revmed-s-pancreatic-cancer-approval-more-mfn-deals 2026-09-02 never 0.6 https://aktiv8.io/news/n1q263zl/norroy-bioscience-initiates-pivotal-phase-iii-clinical-trial-of-177lu-nym032-a-psma-target 2026-09-02 never 0.6 https://aktiv8.io/news/n1x28fj/newron-announces-completion-of-screening-for-enrollment-in-pivotal-phase-3-enigma-trs-1-st 2026-09-02 never 0.6 https://aktiv8.io/news/nhtymkh/novartis-rhapsido-cuts-ms-progression-in-phase-3-trial-teeing-up-roche-battle 2026-09-02 never 0.6 https://aktiv8.io/news/nop72zh/revolution-medicines-announces-nejm-publication-of-phase-1-2-rasonque-data-supporting-ongo 2026-09-02 never 0.6 https://aktiv8.io/news/nt2wu39/novartis-rhapsido-cuts-ms-progression-in-phase-3-trial-teeing-up-roche-battle-biospace 2026-09-02 never 0.6 https://aktiv8.io/news/n1i5nevj/roundup-alteogen-enters-option-license-agreement-with-novartis-newbiologix-synastra-form-b 2026-09-02 never 0.6 https://aktiv8.io/news/n7ixxty/fda-allows-first-gene-therapy-clinical-trial-for-ultra-rare-pediatric-neurodegenerative-di 2026-09-02 never 0.6 https://aktiv8.io/news/nk4t2a6/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-b 2026-09-02 never 0.6 https://aktiv8.io/news/n48glno/scholar-rock-receives-fda-fast-track-designation-for-apitegromab-facioscapulohumeral-muscu 2026-09-02 never 0.6 https://aktiv8.io/news/n1o20mdf/hamamatsu-receives-fda-510-k-clearance-for-nanozoomer-s20md-and-s540md-slide-scanner-syste 2026-09-02 never 0.6 https://aktiv8.io/news/n1fqd3nw/acto-achieves-veeva-gold-product-partner-status-following-a-nearly-decade-long-collaborati 2026-09-02 never 0.6 https://aktiv8.io/news/n1t06mxt/novartis-inks-3-2b-subcutaneous-drug-delivery-deal-with-alteogen 2026-09-02 never 0.6 https://aktiv8.io/news/nhbf5b7/fda-allows-first-gene-therapy-clinical-trial-for-ultra-rare-pediatric-neurodegenerative-di 2026-09-02 never 0.6 https://aktiv8.io/news/naydczw/treeline-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluat 2026-09-02 never 0.6 https://aktiv8.io/news/n12wknuk/inventiva-announces-last-patient-visit-in-nativ3-phase-3-clinical-trial-of-lanifibranor-in 2026-09-02 never 0.6 https://aktiv8.io/news/n1ktsnpp/uniqure-files-for-fda-uk-approval-of-first-gene-therapy-for-huntington-s-disease 2026-09-02 never 0.6 https://aktiv8.io/news/nfqwbil/scholar-rock-receives-fda-fast-track-designation-for-apitegromab-facioscapulohumeral-muscu 2026-09-02 never 0.6 https://aktiv8.io/news/n1r344ys/norroy-bioscience-initiates-pivotal-phase-iii-clinical-trial-of-177lu-nym032-a-psma-target 2026-09-02 never 0.6 https://aktiv8.io/news/nhcclcz/raziel-therapeutics-and-fosun-pharma-announce-positive-phase-3-results-for-rzl-012-in-subm 2026-09-02 never 0.6 https://aktiv8.io/news/n1r47p7t/acto-achieves-veeva-gold-product-partner-status-following-a-nearly-decade-long-collaborati 2026-09-02 never 0.6 https://aktiv8.io/news/n1a464rb/thx-pharma-bbdf-and-biocodex-announce-regulatory-submissions-for-the-phase-3-clinical-tria 2026-09-01 never 0.6 https://aktiv8.io/news/ntus0j1/what-does-biontech-bntx-fda-approval-mean-for-its-2026-covid-vaccine-simplywall-st 2026-09-01 never 0.6 https://aktiv8.io/news/n5xxlir/hiro-and-differentia-biotech-collaborate-on-clinical-trial-simulation-clinical-trials-aren 2026-09-01 never 0.6 https://aktiv8.io/news/nqdwa94/lilly-looks-beyond-obesity-with-up-to-2-9b-acquisition-of-merida-biosciences 2026-09-01 never 0.6 https://aktiv8.io/news/n1bfahgs/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asth 2026-09-01 never 0.6 https://aktiv8.io/news/njy8fdp/alumis-announces-topline-results-from-envudeucitinib-phase-2b-trial-in-systemic-lupus-eryt 2026-09-01 never 0.6 https://aktiv8.io/news/n7rg7jm/simcere-zaiming-roche-ink-license-agreement-for-antibody-targeting-b-cell-mediated-disease 2026-09-01 never 0.6 https://aktiv8.io/news/nbgdieg/ocugen-doses-first-patient-in-ocu410-phase-3-trial-ocgn-stock-news-stock-titan 2026-09-01 never 0.6 https://aktiv8.io/news/n53iys9/blossomhill-therapeutics-to-present-updated-data-from-ongoing-phase-1-2-solara-trial-of-it 2026-09-01 never 0.6 https://aktiv8.io/news/n14l5c0i/ascendis-pharma-strikes-global-settlement-and-licensing-deal-with-biomarin-over-yuviwel-th 2026-09-01 never 0.6 https://aktiv8.io/news/n4j753h/applied-biologics-activates-first-clinical-site-in-phase-3-bioxheal-trial 2026-09-01 never 0.6 https://aktiv8.io/news/n1wre68v/dnak-therapeutics-gatc-health-forge-a-partnership-to-evaluate-accelerate-prioritize-cancer 2026-09-01 never 0.6 https://aktiv8.io/news/n63izxv/intelligent-bio-solutions-achieves-above-98-accuracy-in-method-comparison-study-supporting 2026-09-01 never 0.6 https://aktiv8.io/news/nae5qsx/xentria-advances-xtmab-16-clinical-development-in-pulmonary-sarcoidosis-following-fda-feed 2026-09-01 never 0.6 https://aktiv8.io/news/n10zyo5p/ripple-and-settlemint-partner-to-provide-digital-asset-custody-and-tokenization-for-financ 2026-09-01 never 0.6 https://aktiv8.io/news/n14r7c6m/fda-response-expected-by-mid-september-for-atyr-s-lung-disease-trial-stock-titan 2026-09-01 never 0.6 https://aktiv8.io/news/n7g86gi/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway-tlx-stoc 2026-09-01 never 0.6 https://aktiv8.io/news/ny6aqcg/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-modifier-ge 2026-09-01 never 0.6 https://aktiv8.io/news/n1l41fr/styx-biotechnologies-announces-strategic-agreement-with-zoencure-therapeutics-to-accelerat 2026-09-01 never 0.6 https://aktiv8.io/news/n1a8iq1c/weave-bio-announces-collaboration-with-takeda-to-deploy-ai-native-regulatory-automation-ac 2026-09-01 never 0.6 https://aktiv8.io/news/n1av2e0w/alumis-crushed-by-midstage-lupus-flop-but-plots-path-to-phase-3-for-tyk2-inhibitor 2026-09-01 never 0.6 https://aktiv8.io/news/nqr5rx9/cipla-signs-exclusive-licensing-agreement-with-sbp-group-for-cancer-drug-tqb2102-sahi 2026-09-01 never 0.6 https://aktiv8.io/news/n1pvcyvg/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-modifier-ge 2026-09-01 never 0.6 https://aktiv8.io/news/n1s57y9w/payward-and-london-stock-exchange-to-partner-to-accelerate-uk-equity-markets-through-token 2026-09-01 never 0.6 https://aktiv8.io/news/n1i0o10d/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-modifier-ge 2026-09-01 never 0.6 https://aktiv8.io/news/n148g11w/battelle-researchers-demonstrate-biotech-breakthrough-for-rare-earth-element-separation 2026-09-01 never 0.6 https://aktiv8.io/news/nps9ao4/alumis-crushed-by-midstage-lupus-flop-but-plots-path-to-phase-3-for-tyk2-inhibitor 2026-09-01 never 0.6 https://aktiv8.io/news/n1fjlmm7/stryker-introduces-first-of-its-kind-fda-authorized-surgical-application-for-apple-vision- 2026-09-01 never 0.6 https://aktiv8.io/news/n18bk9cc/atyr-pharma-provides-update-on-timing-of-regulatory-response-for-planned-phase-3-study-of- 2026-09-01 never 0.6 https://aktiv8.io/news/nm5vpk5/thx-pharma-bbdf-and-biocodex-announce-regulatory-submissions-for-the-phase-3-clinical-tria 2026-09-01 never 0.6 https://aktiv8.io/news/n1f0jv4v/medibyt-receives-fda-510-k-clearance-for-cpetwise-advancing-cardiopulmonary-exercise-test- 2026-09-01 never 0.6 https://aktiv8.io/news/n13wgm9g/jazz-reports-phase-iii-trial-interim-results-for-ziihera-combination 2026-09-01 never 0.6 https://aktiv8.io/news/n1xi2lh5/astrazeneca-completes-license-agreement-with-dizal-for-lung-cancer-treatment-zegfrovy-cont 2026-09-01 never 0.6 https://aktiv8.io/news/nygkwea/ascendis-pharma-asnd-clears-yuviwel-patent-fight-with-global-licensing-deal-simplywall-st 2026-09-01 never 0.6 https://aktiv8.io/news/n1m1ne0i/ono-pharma-and-aitia-announce-collaboration-to-identify-novel-drug-targets-in-neurological 2026-09-01 never 0.6 https://aktiv8.io/news/nvtz2vx/ocugen-announces-first-patient-dosed-in-phase-3 2026-09-01 never 0.6 https://aktiv8.io/news/n1tcavi9/roche-finds-another-oncology-gem-in-asia-with-1-5b-b-cell-disease-partnership 2026-09-01 never 0.6 https://aktiv8.io/news/n1vbas3a/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asth 2026-09-01 never 0.6 https://aktiv8.io/news/nwaoko7/eit-pharma-raises-35-million-as-hepatitis-d-candidate-sits-with-fda-the-pharma-letter 2026-09-01 never 0.6 https://aktiv8.io/news/nwj7ldf/pmv-pharma-raises-usd-50-8m-to-fund-rezatapopt-nda-submission-in-q1-2027-allsci 2026-09-01 never 0.6 https://aktiv8.io/news/n8xgqmf/pyrotech-therapeutics-doses-first-subject-in-phase-1-study-of-ptt-121-the-world-s-first-se 2026-09-01 never 0.6 https://aktiv8.io/news/ncjh7pr/ocugen-doses-first-patient-in-global-phase-3-armada3-trial-of-ocu410-for-geographic-atroph 2026-09-01 never 0.6 https://aktiv8.io/news/nmgd68w/parsol-shield-approved-by-fda-dsm-firmenich-setting-a-new-era-for-u-s-sun-protection 2026-09-01 never 0.6 https://aktiv8.io/news/n1rsxa6q/esc-2026-abbott-presents-positive-longer-term-dual-ablation-catheter-data 2026-09-01 never 0.6 https://aktiv8.io/news/n44otrk/cipla-licenses-cancer-bispecific-from-china-s-sino-biopharma-pharma-economictimes-indiatim 2026-09-01 never 0.6 https://aktiv8.io/news/n1uo61u6/lilly-adds-another-m-a-deal-now-to-acquire-merida-biosciences-the-pharma-letter 2026-09-01 never 0.6 https://aktiv8.io/news/n1krbzxe/astrazeneca-completes-global-license-agreement-for-oral-egfr-inhibitor-zegfrovy-sunvozerti 2026-09-01 never 0.6 https://aktiv8.io/news/nu5n660/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asth 2026-09-01 never 0.6 https://aktiv8.io/news/n1qzqfne/orca-bio-to-present-clinical-data-on-tregzi-and-its-clinical-pipeline-at-the-14 2026-09-01 never 0.6 https://aktiv8.io/news/njqvqcw/ascendis-pharma-asnd-clears-yuviwel-patent-fight-with-global-licensing-deal-simplywall-st 2026-09-01 never 0.6 https://aktiv8.io/news/n1jhso35/stat-fda-clears-stryker-s-surgical-cockpit-that-uses-apple-s-vr-headset-vision-pro 2026-09-01 never 0.6 https://aktiv8.io/news/n1qfqo9/atyr-pharma-provides-update-on-timing-of-regulatory-response-for-planned-phase-3-study-of- 2026-09-01 never 0.6 https://aktiv8.io/news/n1djnjug/xentria-advances-xtmab-16-clinical-development-in-pulmonary-sarcoidosis-following-fda-feed 2026-09-01 never 0.6 https://aktiv8.io/news/n1nz4u2b/applied-biologics-activates-first-clinical-site-in-phase-3-bioxheal-trial 2026-09-01 never 0.6 https://aktiv8.io/news/n16m5hou/medibyt-receives-fda-510-k-clearance-for-cpetwise-advancing-cardiopulmonary-exercise-test- 2026-09-01 never 0.6 https://aktiv8.io/news/n18rqgvw/eit-pharma-raises-35-million-as-hepatitis-d-candidate-sits-with-fda-the-pharma-letter 2026-09-01 never 0.6 https://aktiv8.io/news/n10xy7fs/cipla-shares-gain-after-it-inks-cancer-treatment-drug-licensing-deal-with-sino-biopharma-a 2026-09-01 never 0.6 https://aktiv8.io/news/ne819fu/eli-lilly-inks-2-88b-merida-buyout-for-autoimmune-drugs-against-rogue-antibodies 2026-08-31 never 0.6 https://aktiv8.io/news/n801t35/beone-s-cancer-regimen-gets-fda-approval-after-median-survival-exceeded-two-years-stock-ti 2026-08-31 never 0.6 https://aktiv8.io/news/nv17aem/veloxis-pharmaceuticals-doses-first-patient-in-rengevity-201-phase-2-trial-of-pegrizeprume 2026-08-31 never 0.6 https://aktiv8.io/news/ndbs0mv/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/n1ys4x87/karyopharm-seeks-fda-review-for-xpovio-myelofibrosis-use-grafa-com 2026-08-31 never 0.6 https://aktiv8.io/news/nnijqab/fda-approves-gilead-s-new-single-tablet-hiv-regimen-benzinga-com 2026-08-31 never 0.6 https://aktiv8.io/news/n5y1f69/fda-agrees-to-a-placebo-trial-for-a-drug-aimed-at-a-blood-reaction-affecting-50-000-yearly 2026-08-31 never 0.6 https://aktiv8.io/news/n1rw20lp/karmanos-now-offers-fda-approved-daraxonrasib-rasonque-for-metastatic-pancreatic-cancer 2026-08-31 never 0.6 https://aktiv8.io/news/nohesac/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/n1bg45yl/karmanos-now-offers-fda-approved-daraxonrasib-rasonque-for-metastatic-pancreatic-cancer 2026-08-31 never 0.6 https://aktiv8.io/news/n1hthd3o/ideaya-biosciences-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-on-pha 2026-08-31 never 0.6 https://aktiv8.io/news/n16gerp1/positive-phase-3-survival-results-in-her2-advanced-gea-jazz-pharmaceuticals-oncodaily 2026-08-31 never 0.6 https://aktiv8.io/news/n12hy06g/lilly-adds-to-immune-drug-pipeline-with-2-9b-merida-buyout 2026-08-31 never 0.6 https://aktiv8.io/news/n1hb7rxl/fda-oks-takeda-protagonist-drug-for-rare-blood-cancer 2026-08-31 never 0.6 https://aktiv8.io/news/n1dp5vgv/stat-we-re-reading-about-drug-pricing-deals-a-new-cancer-therapy-approval-and-more 2026-08-31 never 0.6 https://aktiv8.io/news/n177lj85/ideaya-biosciences-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-on-pha 2026-08-31 never 0.6 https://aktiv8.io/news/nfu486y/ideaya-biosciences-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-on-pha 2026-08-31 never 0.6 https://aktiv8.io/news/n16q68nf/vertex-pharma-stock-trades-above-540-as-crinetics-merger-clears-key-hurdle-ad-hoc-news 2026-08-31 never 0.6 https://aktiv8.io/news/n1l3j2rx/takeda-protagonist-score-broad-fda-nod-in-rare-blood-cancer-setting-up-2b-opportunity 2026-08-31 never 0.6 https://aktiv8.io/news/nc4225j/axsome-therapeutics-initiates-summit-phase-3-trial-of-axs-05-in-smoking-cessation-axsm-sto 2026-08-31 never 0.6 https://aktiv8.io/news/nfyhx11/palvella-therapeutics-completes-rolling-submission-of-new-drug-application-to-fda-for-qtor 2026-08-31 never 0.6 https://aktiv8.io/news/n17c89ee/stryker-and-iage-partner-to-advance-clinical-excellence-in-fluorescence-guided-surgery-in- 2026-08-31 never 0.6 https://aktiv8.io/news/n1bsazz7/kennedy-wilson-and-shimizu-corporation-partner-on-382-unit-multifamily-development-in-sand 2026-08-31 never 0.6 https://aktiv8.io/news/n1u3zn3v/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-ex 2026-08-31 never 0.6 https://aktiv8.io/news/nfianqf/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/n1uibeg/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/n1qy4hbg/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-meeting-for-phase-3-regis 2026-08-31 never 0.6 https://aktiv8.io/news/n1nczf8f/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-ex 2026-08-31 never 0.6 https://aktiv8.io/news/ndsz77h/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-ex 2026-08-31 never 0.6 https://aktiv8.io/news/n1r70qrw/electra-aims-to-light-up-nasdaq-with-ipo-for-phase-2-3-i-i-push 2026-08-31 never 0.6 https://aktiv8.io/news/n1eeqa69/hiro-and-differentia-biotech-collaborate-on-clinical-trial-simulation 2026-08-31 never 0.6 https://aktiv8.io/news/n7l0aqn/ultra-violette-becomes-first-brand-in-the-us-to-launch-a-sunscreen-containing-newly-fda-ap 2026-08-31 never 0.6 https://aktiv8.io/news/nyjs558/ovarian-cancer-trial-reports-a-46-response-rate-fda-filing-planned-stock-titan 2026-08-31 never 0.6 https://aktiv8.io/news/n1y1q0il/eit-pharma-advances-oral-hepatitis-d-drug-as-fda-accepts-lonafarnib-nda-tipranks 2026-08-31 never 0.6 https://aktiv8.io/news/n1t9db47/endovia-health-sciences-welcomes-historic-shift-in-federal-cannabinoid-policy-advances-can 2026-08-31 never 0.6 https://aktiv8.io/news/nz0040o/change-agents-completes-phase-2-of-its-catch-up-agentic-ai-video-studio-platform-developme 2026-08-31 never 0.6 https://aktiv8.io/news/nbmuusp/beone-medicines-announces-new-phase-3-survival-data-reinforcing-benefit-of-ziihera-contain 2026-08-31 never 0.6 https://aktiv8.io/news/n91sojd/pmv-pharmaceuticals-announces-updated-promising-rezatapopt-monotherapy-interim-ovarian-can 2026-08-31 never 0.6 https://aktiv8.io/news/nsietoz/cadrenal-therapeutics-announces-fda-alignment-on-phase-3-primary-endpoint-for-cad-1005-hit 2026-08-31 never 0.6 https://aktiv8.io/news/n1kzffc1/beone-medicines-announces-new-phase-3-survival-data-reinforcing-benefit-of-ziihera-contain 2026-08-31 never 0.6 https://aktiv8.io/news/n1o4y20h/eit-pharma-closes-oversubscribed-35-million-series-a-round-led-by-propel-bio-partners 2026-08-31 never 0.6 https://aktiv8.io/news/n11pmf7q/cadrenal-therapeutics-announces-positive-outcome-from-fda 2026-08-31 never 0.6 https://aktiv8.io/news/n92we55/eit-pharma-closes-oversubscribed-35-million-series-a-round-led-by-propel-bio-partners 2026-08-31 never 0.6 https://aktiv8.io/news/n1a9627k/biomarin-and-ascendis-pharma-finalize-patent-settlement-with-royalty-license-agreement-kal 2026-08-31 never 0.6 https://aktiv8.io/news/np3mpwt/stockwatch-revolution-shares-stay-flat-despite-historic-fda-approval-of-oral-pancreatic-ca 2026-08-30 never 0.6 https://aktiv8.io/news/n1bgbwb7/arrowhead-pharmaceuticals-presents-phase-3-shasta-3-and-shasta-4-data-demonstrating-plozas 2026-08-30 never 0.6 https://aktiv8.io/news/n1doyefa/fda-approves-protagonist-and-takeda-s-drug-for-rare-blood-cancer 2026-08-30 never 0.6 https://aktiv8.io/news/n1j0kuub/stat-fda-approves-protagonist-and-takeda-s-drug-for-rare-blood-cancer 2026-08-30 never 0.6 https://aktiv8.io/news/nny74pc/arrowhead-pharmaceuticals-presents-phase-3-shasta-3-and-shasta-4-data-demonstrating-plozas 2026-08-30 never 0.6 https://aktiv8.io/news/nm8k1fl/tenax-finds-benefit-in-sicker-patient-subgroup-after-phase-3-trial-miss-tenx-nasdaq 2026-08-30 never 0.6 https://aktiv8.io/news/n40cdss/tenax-therapeutics-tenx-reports-promising-phase-3-trial-data-a-gurufocus 2026-08-30 never 0.6 https://aktiv8.io/news/n2twk7r/cipla-pharma-license-cancellation-fda-withdraws-order-after-hc-raps-it-for-going-overboard 2026-08-29 never 0.6 https://aktiv8.io/news/nbwylg8/a-post-hoc-phase-3-subgroup-analysis-found-tenax-s-drug-cut-a-heart-stress-marker-47-versu 2026-08-29 never 0.6 https://aktiv8.io/news/n18mm5jj/tenax-therapeutics-announces-presentation-of-phase-3-level 2026-08-29 never 0.6 https://aktiv8.io/news/nj54f6t/tenax-therapeutics-presents-additional-phase-3-level-data-showing-tnx-103-benefits-in-ph-h 2026-08-29 never 0.6 https://aktiv8.io/news/n1ndl3fi/tenax-therapeutics-announces-presentation-of-phase-3-level-results-in-late-breaking-scient 2026-08-29 never 0.6 https://aktiv8.io/news/n6v0404/tenax-therapeutics-announces-presentation-of-phase-3-level-results-in-late-breaking-scient 2026-08-29 never 0.6 https://aktiv8.io/news/n81azkg/tenax-presents-additional-phase-3-trial-data-for-tnx-103-investing-com 2026-08-29 never 0.6 https://aktiv8.io/news/n10vltbc/askbio-presents-baseline-characteristics-from-phase-2-heart-failure-gene-therapy-trial-of- 2026-08-29 never 0.6 https://aktiv8.io/news/nd21zeh/tenax-therapeutics-announces-presentation-of-phase-3-level-results-in-late-breaking-scient 2026-08-29 never 0.6 https://aktiv8.io/news/n1lp6m2z/women-leaders-association-adds-lisa-reilly-as-boston-coaching-partner-bringing-23-years-of 2026-08-29 never 0.6 https://aktiv8.io/news/n3nfoac/quoin-pharmaceuticals-reports-positive-interim-data-from-ongoing-phase-2-3-study-of-qrx003 2026-08-28 never 0.6 https://aktiv8.io/news/n1iqq177/durham-biotech-scores-fda-approval-for-potential-blockbuster-drug-the-business-journals 2026-08-28 never 0.6 https://aktiv8.io/news/nmydf1j/zambon-announces-european-commission-approval-of-hopledo-for-adults-with-parkinson-s-disea 2026-08-28 never 0.6 https://aktiv8.io/news/nlbymm9/hagens-berman-alerts-capricor-therapeutics-inc-nasdaq-capr-investors-to-fda-review-extensi 2026-08-28 never 0.6 https://aktiv8.io/news/n6kp5el/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/nlhrvta/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/n1ox8lkz/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/nbsqvi8/byheart-update-fda-confirms-review-of-byheart-s-root-cause-investigation-and-action-plan-f 2026-08-28 never 0.6 https://aktiv8.io/news/n1vghpkq/create-medicines-expands-clinical-in-vivo-car-pipeline-and-lnp-technology-suite-by-forming 2026-08-28 never 0.6 https://aktiv8.io/news/ndpm2tz/novo-nordisk-dominates-oral-obesity-drug-market-pressuring-eli-lilly-with-phase-3-trial-of 2026-08-28 never 0.6 https://aktiv8.io/news/n1xy7w5/ausperbio-adds-120m-series-c-to-advance-hep-b-oligo-therapy-through-phase-3-and-beyond 2026-08-28 never 0.6 https://aktiv8.io/news/n192bvhc/genentech-strikes-second-asia-deal-in-a-week-betting-up-to-1b-in-oncology-adc-alliance-wit 2026-08-28 never 0.6 https://aktiv8.io/news/n18oxjtp/leo-cancer-care-announces-commercial-collaboration-with-leading-healthcare-solutions-provi 2026-08-28 never 0.6 https://aktiv8.io/news/n2eckq7/lilly-joins-novo-in-cardiovascular-space-after-fda-nod-for-glp-1-gip-agonist-mounjaro 2026-08-28 never 0.6 https://aktiv8.io/news/n16vesur/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/nntn6xi/stat-cytokinetics-details-trial-win-for-what-could-be-its-next-approval 2026-08-28 never 0.6 https://aktiv8.io/news/nne9rvz/ausperbio-adds-120m-series-c-to-advance-hep-b-oligo-therapy-through-phase-3-and-beyond 2026-08-28 never 0.6 https://aktiv8.io/news/n2q4o8b/fda-approves-lilly-s-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-typ 2026-08-28 never 0.6 https://aktiv8.io/news/nagmrcn/mbx-biosciences-doses-first-patient-in-phase-3-canvuparatide-trial-for-hypoparathyroidism- 2026-08-28 never 0.6 https://aktiv8.io/news/n1gyjyx5/moderna-raises-2-6b-to-support-cancer-work-fda-clears-updated-covid-vaccines 2026-08-28 never 0.6 https://aktiv8.io/news/n1lp78hi/fda-approves-gilead-s-new-once-daily-hiv-pill-bixlenvo-labroots 2026-08-28 never 0.6 https://aktiv8.io/news/nuwov85/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/n1e97vdv/takeda-receives-u-s-fda-approval-of-mimrylo-rusfertide-marking-a-potential-shift-in-the-tr 2026-08-28 never 0.6 https://aktiv8.io/news/nhyv4v1/pfizer-and-biontech-win-fda-approval-for-xfg-adapted-covid-vaccine-the-pharma-letter 2026-08-28 never 0.6 https://aktiv8.io/news/n1cvdxto/innolitics-and-beacon-neuro-ai-partner-to-bring-fda-breakthrough-device-beaconpredict-to-m 2026-08-28 never 0.6 https://aktiv8.io/news/n17bqddd/gc-biopharma-partners-with-france-s-osivax-to-develop-next-gen-flu-shot-chosunbiz-chosunbi 2026-08-28 never 0.6 https://aktiv8.io/news/nz453fj/natera-and-susan-g-komen-announce-national-partnership-to-accelerate-progress-against-brea 2026-08-28 never 0.6 https://aktiv8.io/news/n1bv75jj/adicet-bio-announces-fda-clearance-of-ind-application-for-adi-212-acet-stock-news 2026-08-27 never 0.6 https://aktiv8.io/news/n1tcuh65/tezspire-hits-both-primary-endpoints-in-phase-3-eosinophilic-esophagitis-trial-the-clinica 2026-08-27 never 0.6 https://aktiv8.io/news/nfytpz0/abbvie-submits-regulatory-application-to-ema-for-skyrizi-risankizumab-subcutaneous-inducti 2026-08-27 never 0.6 https://aktiv8.io/news/n7eoj8f/stat-cassidy-criticizes-fda-oversight-of-abortion-pill-manufacturers-in-new-report 2026-08-27 never 0.6 https://aktiv8.io/news/n15xlxrt/fibrobiologics-releases-third-batch-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ul 2026-08-27 never 0.6 https://aktiv8.io/news/necfi5a/pfizer-and-biontech-receive-u-s-fda-approval-for-xfg-adapted-covid-19-vaccine 2026-08-27 never 0.6 https://aktiv8.io/news/n18l2cxt/fda-approves-roivant-therapy-for-rare-autoimmune-disease 2026-08-27 never 0.6 https://aktiv8.io/news/n1rcd4py/piramal-pharma-renforce-ses-operations-pretes-pour-l-avenir-avec-une-reduction-de-22-6-des 2026-08-27 never 0.6 https://aktiv8.io/news/nwf6ura/kowa-pharmaceuticals-america-announces-fda-acceptance-of-new-drug-application-for-k-911-an 2026-08-27 never 0.6 https://aktiv8.io/news/nlho2lg/psilera-appoints-neuroscience-veteran-allyson-gage-phd-as-vice-president-clinical-developm 2026-08-27 never 0.6 https://aktiv8.io/news/n17oqe4w/psilera-appoints-neuroscience-veteran-allyson-gage-phd-as-vice-president-clinical-developm 2026-08-27 never 0.6 https://aktiv8.io/news/n17y8o5/fibrobiologics-releases-third-batch-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ul 2026-08-27 never 0.6 https://aktiv8.io/news/n4l62mc/kowa-pharmaceuticals-america-announces-fda-acceptance-of-new-drug-application-for-k-911-an 2026-08-27 never 0.6 https://aktiv8.io/news/n9rys22/redx-closes-of-36-million-series-a-financing-ahead-of-skye-merger-the-pharma-letter 2026-08-27 never 0.6 https://aktiv8.io/news/nks4648/rockpoint-and-holland-partner-group-announce-joint-venture-to-develop-stevens-creek-in-san 2026-08-27 never 0.6 https://aktiv8.io/news/n1s0ywx0/akeso-2026-interim-results-strong-commercialization-momentum-io2-0-global-strategy-redefin 2026-08-27 never 0.6 https://aktiv8.io/news/n1f303l0/pfizer-and-biontech-receive-u-s-fda-approval-for-xfg-adapted-covid-19-vaccine 2026-08-27 never 0.6 https://aktiv8.io/news/n1c77d57/innovation-through-collaboration-puts-precision-biologic-on-the-map-in-hemostasis-diagnost 2026-08-27 never 0.6 https://aktiv8.io/news/n6zuxbd/eascra-biotech-awarded-7-96-million-nasa-inspa-phase-2-contract-to-advance-space-manufactu 2026-08-27 never 0.6 https://aktiv8.io/news/n48qcpr/letsgetchecked-powered-by-fuze-health-partners-with-waters-corporation-to-bring-the-most-c 2026-08-27 never 0.6 https://aktiv8.io/news/n963zqb/rongtao-medical-publishes-legacy-ultrasound-cybersecurity-framework-built-on-fda-cisa-and- 2026-08-27 never 0.6 https://aktiv8.io/news/n1ui72v7/innovation-through-collaboration-puts-precision-biologic-on-the-map-in-hemostasis-diagnost 2026-08-27 never 0.6 https://aktiv8.io/news/n17s7lig/fda-inspection-data-reveals-a-new-compliance-blind-spot-for-medical-device-makers 2026-08-27 never 0.6 https://aktiv8.io/news/npjtud6/china-s-akeso-says-cancer-drug-beat-astrazeneca-s-imfinzi-in-phase-3-trial-south-china-mor 2026-08-27 never 0.6 https://aktiv8.io/news/nd7907u/osivax-and-gc-biopharma-enter-strategic-collaboration-to-develop-a-next-generation-influen 2026-08-27 never 0.6 https://aktiv8.io/news/n1k7h2zc/sl-science-highlights-new-fda-drug-master-file-for-gdt-cell-derived-exosomes-expanding-the 2026-08-27 never 0.6 https://aktiv8.io/news/n1fx45fn/mbx-biosciences-announces-first-patient-dosed-in-pivotal-phase-3-optimize-trial-of-once-we 2026-08-27 never 0.6 https://aktiv8.io/news/n1o63io2/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co- 2026-08-27 never 0.6 https://aktiv8.io/news/n2o254/kenorland-minerals-and-targa-exploration-commence-phase-2-drill-program-at-the-opinaca-pro 2026-08-27 never 0.6 https://aktiv8.io/news/ngblzwo/l-innovation-collaborative-propulse-precision-biologic-sur-le-devant-de-la-scene-en-diagno 2026-08-27 never 0.6 https://aktiv8.io/news/n1tp1tyz/nicox-announces-april-2027-pdufa-date-for-ncx-470-in-glaucoma-the-manila-times 2026-08-27 never 0.6 https://aktiv8.io/news/n388asr/uniphore-and-tech-mahindra-partner-to-deliver-an-agentic-ai-factory-for-the-enterprise 2026-08-27 never 0.6 https://aktiv8.io/news/n1gnzpdi/nicox-announces-april-2027-pdufa-date-for-ncx-470-in-glaucoma 2026-08-27 never 0.6 https://aktiv8.io/news/n3z6yu5/verrica-completes-enrollment-in-phase-3-ycanth-common-warts-trial-dermatology-times 2026-08-27 never 0.6 https://aktiv8.io/news/n120hnbv/biohaven-sk-biopharma-sign-kv7-licensing-deal-voice-of-healthcare 2026-08-27 never 0.6 https://aktiv8.io/news/ngvqttq/stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump-deal-with- 2026-08-27 never 0.6 https://aktiv8.io/news/naf46i5/amgen-tezspire-phase-3-trial-shows-eoe-improvements-grafa-com 2026-08-27 never 0.6 https://aktiv8.io/news/n15lj2ot/cytomx-therapeutics-announces-fda-fast-track-designation-for-varsetatug-masetecan-varseta- 2026-08-27 never 0.6 https://aktiv8.io/news/nk9e411/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co- 2026-08-27 never 0.6 https://aktiv8.io/news/n1e2mn63/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-m 2026-08-27 never 0.6